Although the multi-functional, prosurvival protein, Bcl-2-associated anthanogene 1 (BAG-1) is frequently overexpressed in breast cancers, its role in the development or maintenance of the malignant state remains unclear. Here, we have used the established MCF-10A 3-dimensional (3D) model of mammary morphogenesis as a biologically relevant system to determine how BAG-1 expression may influence the development of breast cancer. When cultured in 3D, MCF-10A cells undergo a highly regulated morphogenic program leading to the development of polarized acinar structures containing a central, hollow lumen formed, in part, through the induction of BIM-dependent apoptosis. BAG-1 overexpression resulted in an attenuation of this normal apoptotic program characterized by a significantly increased number of acini with filled lumens-a phenotype commonly observed in ductal carcinoma in situ. BAG-1's effects were associated with an activation of RAF-1-a known binding partner of BAG-1, enhanced signaling through the MAP kinase pathway and a decrease in BIM expression. Reversal of the BAG-1-associated survival phenotype by the mitogen-activated kinase/ERK kinase inhibitor, U0126, implicates the RAF-1-extracellular signal-regulated kinase signaling pathway as a major mediator of BAG-1's effects in this model. As BAG-1 expression is often elevated in preinvasive breast cancers, these findings support a possible role for BAG-1 as an early contributor to the malignant process in the breast.
Introduction
BAG-1 (BCL-2-associated anthanogene 1) is a prosurvival protein that was first identified as a binding partner of BCL-2 (Takayama et al., 1995) and the activated glucocorticoid receptor (Zeiner and Gehring, 1995) , and has subsequently been shown to have pleiotropic effects on a diverse range of cellular responses, including apoptosis, transcription, proliferation and signaling (Townsend et al., 2003b) .
The BAG-1 gene encodes three major protein isoforms: designated BAG-1S (36 kDa), BAG-1M (46 kDa) and BAG-1L (50 kDa), which are generated by alternate translation initiation from a single mRNA molecule and share a common carboxy terminus (Townsend et al., 2003b) . The latter contains the 'BAG domain', a region that has a key role in mediating many of BAG-1's cellular effects. Interaction between BAG-1 and the heat shock proteins, HSC70 and HSP70, is mediated through the BAG domain and it regulates the refolding of denatured substrate proteins into functional conformations, particularly in response to cellular stress (Ho¨hfeld, 1998) . It is also the region mediating interactions between BAG-1 and the serine/threonine protein kinase, RAF-1 (Wang et al., 1996; Song et al., 2001) , with evidence of competition between RAF-1 and HSP70 for BAG-1 binding (Song et al., 2001) . Ras-induced activation of RAF-1 transmits proliferative and prosurvival signals from extracellular, mitogenic growth factors leading to the activation of mitogen-activated kinase/ERK kinase (MEK) and extracellular signalregulated kinase (ERK; for review, see Kolch (2000) ). However, BAG-1's activation of RAF-1 is independent of Ras signaling and is negatively regulated by HSP70 (Song et al., 2001) , thus possibly defining a new link between the cellular stress response and the regulation of cell growth and survival.
The unique amino terminus of BAG-1 mediates the intracellular localization of the isoforms with BAG-1L containing a nuclear localization signal consistent with its predominantly nuclear expression, and BAG-1S and BAG-1M (both lacking the nuclear localization signal) located in the cytoplasm and cytoplasm/nucleus, respectively (Packham et al., 1997; Takayama et al., 1998) . This differential localization may also dictate functional differences between the isoforms. For example, only BAG-1L interacts with the nuclear hormone receptors, estrogen receptor (ER) and androgen receptor leading to an enhancement in their transcriptional activity (Froesch et al., 1998; Cutress et al., 2003) .
One of the most commonly studied of BAG-1's cellular functions is its effect on cellular survival, although the underlying molecular mechanisms involved are yet to be fully elucidated. BAG-1 is induced by a variety of survival signals and suppresses apoptosis initiated by a diverse range of stimuli, including chemotherapeutic agents such as etoposide and cisplatin, radiation, death receptor activation and growth factor withdrawal (for review, see Townsend et al. (2003b) ).
There are a number of possible mechanisms by which BAG-1 may mediate its pro-survival effects. It is known to interact with and enhance the activity of the antiapoptotic regulator, BCL-2 (Takayama et al., 1995) , with evidence of their colocalization at the mitochondria -the key organelle involved in regulating the intrinsic apoptotic pathway. It has also been suggested that BAG-1-HSP70 complexes may enhance the activity of BCL-2 by effecting a conformational change in the latter (Takayama et al., 1997) , although direct evidence for this is lacking. Certainly, BAG-1's interactions with the molecular chaperones, HSP70 and HSC70, seem to be important for its prosurvival function as mutation of the heat shockprotein-binding site in BAG-1S abrogates its ability to protect against heat shock-induced apoptosis (Townsend et al., 2003a) . Furthermore, as BAG-1's interaction with RAF-1 was maintained in these experiments, it would suggest that BAG-1-induced RAF-1 activation is not critical for anti-apoptotic signaling, at least in this context. However, this may well be a cell type-and stimulus-specific effect, as RAF-1 is known to elicit prosurvival signals through ERK-mediated phosphorylation of pro-and anti-apoptotic effectors such as BAD, BIM and BCL-2 (Kolch, 2000) . Recently, Wang et al. demonstrated BAG-1's ability to interact with and inhibit the transactivating function of p73, suggesting that this may contribute to BAG-1-mediated survival given p73's known role as a regulator of stress-induced apoptosis (Wang et al., 2009) . Thus, BAG-1's prosurvival effects are likely to be mediated through multiple pathways depending on the cellular context and reflecting its numerous and varied binding partners.
The dysregulation of apoptotic signaling pathways is a hallmark of breast cancer like many other malignancies (Hanahan and Weinberg, 2000) , and several clinical studies by us and others have attempted to delineate the role of BAG-1 as a potential prognostic or predictive marker in this context. One consistent finding from both in vitro and clinical studies is that BAG-1 expression is elevated in breast cancer compared with normal breast epithelium Yang et al., 1999; Turner et al., 2001; Millar et al., 2008) . Furthermore, overexpression of the BAG-1S and BAG-1L isoforms in the ER-positive breast cancer cell line, ZR-75-1, significantly enhanced tumor growth in murine xenograft studies compared with control-transfected cells (Kudoh et al., 2002) . Interestingly, BAG-1 expression is also elevated in preinvasive breast cancers such as ductal carcinoma in situ, as well as precancerous breast lesions (Brimmell et al., 1999) , suggesting it may have a role at an early stage in the malignant process. However, the exact nature of BAG-1's effects on the development of breast cancer and the mechanistic basis for its actions in this context remain ill defined. In an attempt to address this, we have used an established three-dimensional (3D) model of mammary epithelial morphogenesis in the immortalized mammary epithelial cell line, MCF-10A (Debnath and Brugge, 2005) , to determine how BAG-1 expression might influence key processes leading to breast cancer development in a biologically relevant context. Here we show that BAG-1 expression significantly attenuates the normal apoptotic program in 3D acinar structures, with evidence that this is driven by enhanced activation of RAF-1 signaling and decreased expression of the pro-apoptotic effector, BIM.
Results
Elevated BAG-1 mRNA and protein expression in breast cancer cell lines compared with normal and immortalized mammary epithelial cells BAG-1 mRNA and protein expressions were examined in a panel of cancer (both ER-positive and ERnegative), normal and immortalized breast cell lines by quantitative real-time PCR and immunoblot, respectively. All three of the major BAG-1 protein isoforms (BAG-1L, BAG-1M and BAG-1S) were detected at varying degrees in all of cell lines examined. Figures 1a and b demonstrate that there was a significant increase in BAG-1 mRNA and protein expression in breast cancer cell lines compared with normal and immortalized breast cells, and supports data from previous studies (Brimmell et al., 1999; Yang et al., 1999) . However, no significant differences in BAG-1 expression were observed between ER-positive and ER-negative breast cancer cell lines (data not shown). Interestingly, we did observe differences between mRNA and protein expression levels in the different cell lines, for example, MDA-MB-468 cells have relatively high levels of mRNA but relatively low levels of BAG-1 protein. These results support data from studies on primary breast cancers (Townsend et al., 2002) , and suggest that posttranslational control mechanisms are important in dictating BAG-1 expression.
To determine the effects of BAG-1 expression on the malignant process in the breast, BAG-1 was expressed in the immortalized human mammary epithelial cell line, MCF-10A, by retroviral infection. Figure 1c demonstrates that all three major BAG-1 protein isoforms were expressed in MCF-10A/BAG-1 cells at levels comparable with or higher than those observed in breast cancer cell lines.
BAG-1 expression attenuates luminal apoptosis in 3D cultures When cultured on reconstituted basement membrane (Matrigel; BD Biosciences, San Jose, CA, USA), MCF-10A cells undergo a well-defined morphogenic program leading to the development of polarized acinar structures with a hollow lumen, resembling the mammary lobules in the human breast. The lumen is formed by apoptosis driven by the pro-apoptotic BH3-only protein, BIM and characterized by the expression of active caspase-3 (Debnath and Brugge, 2005) .
We examined the effects of BAG-1 expression on luminal apoptosis in 3D acini using both morphological and biochemical markers of this process. First, we determined the amount of luminal clearing in BAG-1-expressing and vector control acini at day 20 of 3D culture when completely hollow lumens are normally present (Mailleux et al., 2008) . Figure 2a shows representative confocal images of partial lumen formation in MCF-10A/BAG-1 acini compared with complete lumen formation in MCF-10A/VEC acini. The quantification of lumen formation revealed a significant increase in acini showing no luminal clearing and significant decrease in partial or fully-cleared lumen in BAG-1-expressing acini compared with vector controls (Figure 2a) .
Luminal apoptosis was also detected and quantified by immunostaining with an antibody against M30, a molecular marker of apoptosis that detects caspasecleaved cytokeratin 18. Under normal conditions, cells in the central luminal space undergo apoptosis between days 7 and 10 of 3D culture (Debnath and Brugge, 2005) . BAG-1-expressing acini displayed significantly reduced levels of M30 staining (defined as containing four or more M30-positive cells) at days 7 and 10 of 3D culture compared with vector control acini ( Figure 2b ). In addition, immunoblot of whole-cell lysates from MCF-10A/VEC and BAG-1-expressing acini showed that BAG-1 expression was associated with significantly decreased levels of activated caspase-3 at these same time points compared with vector controls (Figure 2c ).
BAG-1-mediated attenuation of luminal apoptosis is associated with increased RAF-1 activation BAG-1 binds to and activates the serine/threonine protein kinase, RAF-1 in vitro (Wang et al., 1996; Song et al., 2001) , which itself can enhance cellular survival signals through ERK-mediated phosphorylation and inactivation of BIM (Kolch, 2000) . Thus, to explore a possible mechanistic basis for BAG-1's effects on MCF-10A survival, we examined the phosphorylation of RAF-1 by immunoblotting of cell lysates from MCF-10A/VEC and MCF-10A/BAG-1 acini at days 7 and 10 of 3D culture. Although activation of RAF-1 occurs by phosphorylation at multiple activating sites, serine 338 (S338) is one of the first sites to be phosphorylated (Avruch et al., 1994) . A significant increase in RAF-1 S338 phosphorylation was observed in BAG-1-expressing acini at both time points compared with vector control acini (Figure 3a and b) . We then determined whether this was associated with a direct interaction between RAF-1 and BAG-1. Co-immunoprecipitation studies were not readily feasible in 3D culture because of the large numbers of cells required for optimal results. However, RAF-1 and BAG-1 were specifically co-immunoprecipitated from MCF-10A/ BAG-1 cells grown in monolayer culture (Figure 3c ) under conditions that mimic the 3-D environment, in which epidermal growth factor is essential for acinar morphogenesis (Brummer et al., 2006) . We also examined the intracellular expression of BAG-1 and RAF-1 in MCF-10A by immunocytochemistry and observed a colocalization between the two proteins in MCF-10A/ BAG-1 cells (Figure 3d ), providing further evidence BAG-1-mediated survival is associated with increased ERK1/2 phosphorylation and decreased BIM expression To further explore the role of RAF-1 activation in mediating BAG-1's pro-survival effects, we examined downstream components of the MEK-ERK signaling cascade, namely increased phosphorylation of ERK1/2 and decreased expression of BIM EL (Kolch, 2000) .
Figures 4a and b demonstrate that BAG-1 expression was associated with a significant increase in ERK1/2 phosphorylation at days 7 and 10 of 3D culture when compared with vector control acini. In addition, a significant decrease in BIM EL expression was observed at these time points in MCF-10A/BAG-1 acini compared with MCF-10A/VEC acini (Figures 4a and c) . These data suggest that BAG-1 expression is associated with enhanced signaling through the MEK-ERK signaling pathway downstream of RAF-1 activation.
Enhanced phosphorylation of BIM EL in BAG-1-expressing acini BIM is a critical effector of luminal cell death in MCF-10A acini (Reginato et al., 2005) . Its expression is regulated by ERK-mediated phosphorylation on serine 69 (S69), which subsequently targets it for proteasomal degradation (Ley et al., 2003; Luciano et al., 2003) . BIM has a relatively short half-life (Meller et al., 2006) , thus to enable optimal observation of BIM S69 phosphorylation, we blocked the activity of the proteasome using the proteasome inhibitor MG132 and examined expression of BIM at the earlier time points of days 5 and 6 of 3D culture. The cell cycle regulator, p21
, was used as a positive control in these experiments, as it is known to be rapidly degraded by the proteasome (Blagosklonny et al., 1996) . Figure 5b demonstrates that addition of MG132 resulted in an increase in BIM EL S69 phosphorylation in both MCF-10A/BAG-1 and MCF-10A/VEC acini compared with vehicletreated acini, however, this effect was significantly enhanced in BAG-1-expressing cells compared with vector controls.
MEK inhibition restores luminal apoptosis in BAG-1-expressing acini
To further establish the role of MEK-ERK activation in mediating BAG-1's prosurvival effects, we investigated the effects of the MEK inhibitor, U0126, on the BAG-1-induced phenotype in 3D culture. MCF-10A/BAG-1 and MCF-10A/VEC acini were treated with U0126 and whole-cell lysates were prepared for protein analysis at days 6 and 10 of 3D culture. Treatment of BAG-1-expressing acini with the vehicle (dimethyl sulfoxide) confirmed our earlier observations of an increase in ERK1/2 phosphorylation and decrease in BIM EL expression compared with vector control acini at both time points (Figures 6a and 4a) . However, treatment with U0126 attenuated both these effects in BAG-1-expressing acini and levels of both phosphorylated ERK1/2 and BIM EL were similar to levels observed in vector control cells (Figure 6a ), confirming that active MEK-ERK signaling had been inhibited.
We then determined the effects of MEK inhibition on BAG-1-mediated survival using M30 expression at day 10 of 3D culture as a marker of acinar apoptosis. Data from vehicle-treated acini confirmed our earlier results that BAG-1 expression significantly attenuates apoptosis compared with vector control cells (Figures 6b and c,  and 2a) . However, treatment with U0126 ablated this survival effect and BAG-1-expressing acini displayed levels of apoptosis similar to those observed in vector control acini (Figure 6c ). Thus, these data suggest that the BAG-1-induced survival phenotype in MCF-10A 3D acini is mediated via active MEK-ERK signaling leading to a decrease in BIM EL expression through S69 phosphorylation and proteasomal degradation, and the subsequent loss of apoptotic signals in the central luminal space (Figure 7 ).
Discussion
The multi-functional, prosurvival protein, BAG-1 is commonly overexpressed in breast cancers (Sharp et al., 2004) . However, although the dysregulation of apoptotic signaling cascades is a hallmark of malignancy (Hanahan and Weinberg, 2000) , the role of BAG-1 in the development or progression of breast cancer remains ill defined. Here we have used the MCF-10A 3D model of mammary epithelial morphogenesis to address this and to further elucidate the mechanistic basis for BAG-1's actions in this context. This 3D model recapitulates many of the normal, morphogenic features of the mammary epithelium in vivo, including the formation of polarized spheroid structures or 'acini' containing a central, hollow lumen formed through a well-defined apoptotic program (Debnath et al., 2002; Mailleux et al., 2008) , and has been used effectively to elucidate the role of oncogene-driven signaling pathways in the malignant process in a biologically relevant context (Debnath and Brugge, 2005) .
The overexpression of BAG-1 in MCF-10A cells led to an attenuation of luminal apoptosis-characterized by an increased number of acini with filled lumens and a decrease in molecular markers of apoptosis such as M30 and activated caspase-3. This phenotype typifies those seen in most breast carcinomas and preinvasive lesions such as ductal carcinoma in situ, as well as some precancerous states such as atypical ductal hyperplasia (Harris et al., 1999) , suggesting that disruption of the normal apoptotic program may have an important role in the initiation and progression of breast cancer. Studies aimed at elucidating the molecular mechanisms governing the formation and maintenance of the luminal space have demonstrated that it may be influenced both by Akt-mediated survival signals in the matrix-associated outer cells (Debnath et al., 2002) and active, BIMmediated apoptotic signals in the centrally localized cells (Reginato et al., 2005; Mailleux et al., 2007) . BIM is upregulated immediately before the initiation of apoptosis and is specifically inhibited by prosurvival oncoproteins through stimulation of MEK-ERK signaling (Reginato et al., 2005) . However, overexpression of antiapoptotic regulators, such as BCL-2 and BCL-XL, only delays but does not completely ablate luminal apoptosis in 3D acini (Debnath et al., 2002) . The latter requires an enhancement of both proliferative and anti-apoptotic cues such as those provided by the epidermal growth factor receptor, ERBB2/HER2 (Muthuswamy et al., 2001) , or through co-expression of proliferation and survival proteins (Debnath et al., 2002) .
Thus, these data demonstrating that BAG-1 expression maintains luminal filling up to 20 days in 3D culture suggest that it may elicit this phenotype by influencing pathways controlling both cellular survival and proliferation-a concept further supported by our observations of enhanced RAF-1 activation in BAG-1-expressing acini. Signaling cascades downstream of RAF-1 are known to influence both mitogenic and anti-apoptotic pathways, for example, through the regulation of the proliferative genes FOS and MYC and the apoptotic regulators BAD, BIM and BCL-2 (Kolch, 2000) , and although this study predominantly focused on apoptotic endpoints, it is plausible that BAG-1's interactions with RAF-1 are influencing both these processes in 3D acini. In addition, BAG-1 directly interacts with the cell-cycle regulatory protein, Retinoblastoma (Arhel et al., 2003) that itself is a RAF-1 substrate (Wang et al., 1998) and increases the proliferation rate of neuronal precursor cells (Elliott and Ginzburg, 2009 ). and vector control (V) acini at days 6 and 10 of 3D culture after treatment with U0126 or vehicle control (dimethyl sulfoxide; DMSO). b-actin was used as an additional loading control. Graphs show densitometry of phosphorylated ERK1/2 and BIM EL expression at day 10 normalized to total ERK or b-actin in MCF-10A/BAG-1 (black bars) and MCF-10A/VEC (white bars) acini from at least two independent experiments. Error bars indicate s.e.m., *Po0.05; **Po0.02 for BAG-1-expressing acini versus vector controls. (b) Representative equatorial confocal cross-sections showing M30 (apoptosis), BAG-1 and 4 0 ,6-diamidino-2-phenylindole (DAPI) staining in BAG-1-expressing and vector control acini at day 10 of three-dimensional (3D) culture after treatment with the mitogenactivated kinase/ extracellular signal-regulated kinase kinase (MEK) inhibitor, U0126, or vehicle control (dimethyl sulfoxide, DMSO). Overlays of selected sections are shown in white boxes. Scale bars ¼ 100 mm. (c) Graph represents quantification of positive M30 staining (containing X4 M30-positive cells) in MCF-10A/BAG-1 (black bars) and MCF-10A/VEC (white bars) acini at day 10 from at least three independent experiments. Error bars indicate s.e.m., **Po0.005 for BAG-1-expressing acini versus vector controls.
Attenuation of the BAG-1-associated survival phenotype by the MEK inhibitor, U0126, confirms that the RAF-1 signaling cascade is a major pathway through which BAG-1 mediates its effects in this model. Although this is in contrast to BAG-1's role in protecting against heat shock-induced apoptosis, in which its survival effects are dependent on HSP70/ HSC70 binding and not on interaction with RAF-1 (Townsend et al., 2003a) , it is perhaps not surprising given the pleiotropic nature of BAG-1's actions and those of its interacting partners, and it emphasizes the importance of delineating the functional effects of BAG-1 in a context-specific manner. This is further reflected by the fact that known regulators of BAG-1/ RAF-1 survival signaling in other cell types, such as BCL-2 or BAD, were not altered in BAG-1-expressing MCF-10A cells (data not shown), suggesting that BIMmediated effects may predominate in this model. Given the strong phenotypic correlations between the MCF-10A 3-D model and mammary morphogenesis in vivo (Debnath and Brugge, 2005) , these data also suggest that the BAG-1-RAF-1 interaction may be of importance in the early phases of breast cancer development through a disruption in the normal cellular architecture of the mammary gland. Indeed, the elevated levels of BAG-1 expression observed in early breast lesions and preinvasive breast cancers such as ductal carcinoma in situ (Brimmell et al., 1999) would further support a role for BAG-1 in the development of breast carcinogenesis. Interestingly, several studies have also shown increased MAP kinase activity in breast cancers compared with benign breast tissue (Sivaraman et al., 1997; Salh et al., 1999; Mueller et al., 2000) , with evidence that in at least some cases, this is independent of Ras mutations or elevated growth factor receptor expression (Mueller et al., 2000) . We would postulate on the basis of our data that BAG-1 overexpression may provide an alternative mechanism by which enhanced MAP kinase signaling is initiated in breast cancers. Thus, further studies examining the correlation between BAG-1 expression and RAF-1 or MAP kinase activity in breast cancer tissue would be of interest.
Although these experiments were primarily focused on the role of BAG-1 in the development of the malignant process in the breast, it is nonetheless of interest to speculate how they may relate to the association between high BAG-1 expression and improved outcome for breast cancer patients observed by us and others (Turner et al., 2001; Cutress et al., 2003; Millar et al., 2008; Nadler et al., 2008) . One possible explanation for this apparent dichotomy lies in the inherent heterogeneity in BAG-1's actions, such that its pro-survival effects may have an important role during tumor initiation, but lead to the formation of a less aggressive or more therapeutically responsive cancer, for example, through its known effects on nuclear hormone receptor function. However, interpretation of immunohistochemical studies of BAG-1 expression in breast cancer tissue are also confounded by differences in the intracellular localization and hence, possibly the BAG-1 isoform being detected, await analyses using isoformspecific antibodies to be fully resolved. It would also be of further interest to determine which of the three major isoforms of BAG-1 are mediating the effects observed in our 3D model.
In summary, we have demonstrated that expression of BAG-1 in immortalized mammary epithelial cells grown in 3D cultures phenocopies changes observed in preinvasive breast cancers such as ductal carcinoma in situ, namely a decrease in apoptosis and a filling of the central luminal space. As illustrated in Figure 7 , these effects are mediated through the activation of the serine/ threonine kinase RAF-1, with supporting evidence of a direct interaction with BAG-1. This leads to the subsequent activation of a downstream signaling cascade through the phosphorylation of MEK and ERK1/2. The latter phosphorylates BIM EL on serine 69 targeting it for proteasomal degradation, resulting in the loss of normal apoptotic signals in the lumen and a filled luminal space. Thus, these studies not only provide important new insight into the factors governing breast cancer development, but also suggest that targeting BAG-1 or BAG-1-RAF-1 interactions may provide an effective new strategy for therapeutic intervention. Figure 7 A schematic representation of the putative intracellular signaling pathways mediating Bcl-2-associated anthanogene 1 (BAG-1) effects on the apoptotic program during MCF-10A morphogenesis in three-dimensional (3D) culture. Increased expression of BAG-1 results in an activation of RAF-1 through the phosphorylation of serine 338 (S338). This initiates a downstream signaling cascade resulting in enhanced phosphorylation of BIM EL on serine 69 (S69) by activated ERK1/2. Phosphorylated BIM EL is rapidly targeted for proteasomal degradation leading to a decrease in its expression levels and a loss of normal pro-apoptotic signaling in the luminal space. The mitogen-activated kinase/ extracellular signal-regulated kinase kinase (MEK) inhibitor, U0126, blocks the activity of MEK and extracellular signalregulated kinase 1/2 (ERK1/2) resulting in a restoration of BIM EL expression and activity, and the formation of hollow acinar structures through activation of apoptosis in the central luminal space.
Materials and methods

Human breast cell lines
The panel of normal, immortalized and breast cancer cell lines ( Figure 1 ) were all obtained from ATCC (American Type Culture Collection, Manassas, VA, USA) except HMEC 219-4 (Clonetics, Lonza Australia, Mt Waverley, VIC, Australia), HMEC 184, HMEC 184-A1 and HMEC 184-B5 (a kind gift from Dr Martha Stampfer, Berkeley, CA, USA). Characteristics of these cell lines have been described previously (Sutherland et al., 1999) .
Retroviral vectors
A complementary DNA insert encoding human BAG-1 (cat no. SC107955; OriGene Technologies, Rockville, MD, USA) was subcloned into EcoR1 and Not1 sites in the gateway vector pENTR2B. LR clonase recombination reaction was then used to transfer the complementary DNA insert encoding human BAG-1 into the retroviral vector pQCXIP (Invitrogen, Carlsbad, CA, USA).
Cell culture and retroviral infection of MCF-10A cells MCF-10A and MCF-10A/EcoR cells (MCF-10A cells expressing the ecotropic retroviral receptor; a kind gift from Drs Danielle Lynch and Joan Brugge, Department of Cell Biology, Harvard Medical School, Boston, MA, USA), were routinely maintained in monolayer culture in Dulbecco's modified Eagles's medium/nutrient mixture F-12 (Invitrogen) supplemented with 5% (v/v) horse serum (Invitrogen), 100 ng/ml cholera toxin (Sigma, St. Louis, MO, USA), 20 ng/ml human recombinant epidermal growth factor (R&D Systems, Minneapolis, MN, USA), 0.5 mg/ml hydrocortisone (Sigma), 50 U/ ml penicillin G (Invitrogen), and 50 mg/ml streptomycin sulfate (Invitrogen). For co-immunoprecipitation studies, cells were serum-starved in 0.4% (v/v) horse serum for 18 h before addition of 100 ng/ml epidermal growth factor for 5 mins. For 3D cultures, MCF-10A cells were grown as previously described (Debnath et al., 2003) .
Retrovirus was constructed essentially as previously described (Brummer et al., 2006) . Briefly, the ecotropic packaging cell line PlatE was transfected with the BAG-1 construct using Fugene (Roche, Nutley, NJ, USA). Retrovirus was collected 48 h post-transfection, diluted with medium and then added to subconfluent MCF-10A/EcoR cells. Infected cells were selected for 1 week in puromycin (2 mg/ml; Life Technologies, Carlsbad, CA, USA) to yield stable retroviral pools.
The 3D cultures were generated by plating single-cell suspensions into chamber slides (BD Falcon, Franklin Lakes, NJ, USA) that had been previously coated with a thin-layered growth factor-reduced Matrigel (BD Biosciences). The day of plating was taken as day 0 and the medium was replaced every 4 days. Inhibitors were added as follows: U0126 (0.5 mM; Sigma) at the specified dose on day 5 of 3D culture, and the medium was replaced every 2 days after; MG132 (50 mM; R&D Systems) 5 h before collection.
Analysis of 3D matrigel cultures by confocal microscopy For confocal microscopy, acini were fixed and stained using the indicated antibodies as described earlier (Debnath et al., 2003) . Acini were then stained using the appropriate Cy3-or Cy2-labeled secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and 4 0 ,6-diamidino-2-phenylindole as a DNA counterstain. Antibody specificity was confirmed by using the following controls: primary antibody with no secondary labeled antibody and secondary labeled antibody with no primary antibody. Confocal microscopy was performed using either Leica DMRBE (SP1) or Leica DMIRE2 (SP2 AOBS) confocal microscope (Leica Microsystems, North Ryde, NSW, Australia). For colocalization studies, analysis was performed by compiling multiple high-resolution z stacks of x and y plane confocal scans using Leica confocal software. M30 was quantified by scoring at least 100 structures using a fluorescence microscope. Acini that contained more than four M30-positive cells were scored as positive.
Acini were collected essentially as previously described (Caldon et al., 2008) . Briefly, Matrigel was dissolved using cell recovery solution (BD Biosciences) following the manufacturer's instructions. Chamber slides were then washed in phosphate buffered saline and the acini were collected by centrifugation and then lysed using ice-cold lysis buffer (50 mmol/l HEPES (pH 7.4), 0.1% (w/v) SDS, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 5 mmol/l EDTA, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mmol/l phenylmethylsulfonyl fluoride, 50 mmol/l sodium fluoride, and 1 mmol/l sodium orthovanadate).
Real-time quantitative PCR Total RNA was isolated using the RNAeasy kit (Qiagen, Doncaster, VIC, Australia) and was reverse-transcribed using the Reverse Transcription System (Promega, Alexandria, NSW, Australia) according to manufacturer's instructions. Real-time PCR was performed with an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using inventoried (pre-made) Taq-Man probes for BAG-1 (Applied Biosytems). Data analyses were performed using the DDC t method with RPLPO (Applied Biosystems) as an internal loading control. Fold changes in gene expression were calculated relative to untreated controls.
Western blot analysis
Whole cell protein lysates (10-30 mg) were separated using NuPAGE polyacrylamide gels (Invitrogen) and transferred to polyvinylidine difluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA) using standard methods.
Antibodies
Antibodies against phospho-Ser 69 BIM, phospho-Ser 338 RAF-1, phosphorylated and total p42/44 ERK, MEK1/2, and cleaved caspase-3 were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-BIM antibody was purchased from Calbiochem (San Diego, CA, USA). Anti-BAG-1 antibodies (clone 3.10G3E2, immunoblotting and Y166, immunofluorescence) were purchased from Chemicon International (Billerica, MA, USA) and Abcam (Cambridge, MA, USA), respectively. Anti-RAF-1 (C12) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-M30 CytoDEATH antibody was purchased from Alexis Biochemicals (San Diego, CA, USA); anti-b-actin (Clone AC-15) antibody was purchased from Sigma; antip21 WAF1/CIP1 (C24420) and anti-b-catenin antibodies were purchased from BD Biosciences.
Immunoprecipitation MCF-10A/VEC and MCF-10A/BAG-1 cells were grown in monolayer, collected and immunoprecipitated using 2 mg of either anti-RAF-1 (C-12) antibody or negative control (normal rabbit IgG; Santa Cruz Biotechnology) essentially as previously described (Townsend et al., 2003a) .
